	US 12,473,368 B2
	CD25 antibodies
Ramesh Baliga, Redwood City, CA (US); Leonard George Presta, San Francisco, CA (US); Phung Tu Gip, San Francisco, CA (US); Hanako Daino-Laizure, San Jose, CA (US); Piotr J. Zalicki, Belmont, CA (US); and Oleg Gurinovich, San Leandro, CA (US)
Assigned to iBio, Inc., San Diego, CA (US)
Filed by iBio, Inc., Bryan, TX (US)
Filed on Nov. 12, 2021, as Appl. No. 17/524,852.
Claims priority of provisional application 63/113,784, filed on Nov. 13, 2020.
Prior Publication US 2022/0153852 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2866 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)]

12 Claims

1. A humanized antibody or binding fragment thereof, that binds human CD25, wherein the antibody or binding fragment thereof comprises a variable heavy chain comprising SEQ ID NO: 2, 3, 4, 5, or 6 and a variable light chain comprising SEQ ID NO: 8 or 9.